Retour sur lavenir.net
   KINEPOLIS GROUP 36.500 € (+2,67 %)     SHURGARD 26.500 € (+0,76 %)     ASCENCIO 52.100 € (+0,39 %)     AGEAS 70.400 € (+0,93 %)     XIOR 26.750 € (+1,33 %)     AZELIS GROUP 9.675 € (+2,98 %)     ARGENX SE 825.200 € (+3,98 %)     AB INBEV 71.120 € (-0,14 %)     ACKERMANS V.HAAREN 280.600 € (+0,65 %)     CARE PROPERTY INV. 12.760 € (+1,43 %)     AEDIFICA 69.650 € (-1,00 %)     KBC ANCORA 83.600 € (+0,60 %)     VGP 87.100 € (+3,57 %)     SOFINA 229.200 € (+0,44 %)     VIOHALCO 18.900 € (+0,85 %)     UMICORE 20.860 € (+0,97 %)     JENSEN-GROUP 84.600 € (0,00 %)     HOME INVEST BE. 19.260 € (+0,73 %)     PROXIMUS 5.875 € (+1,73 %)     RETAIL ESTATES 69.000 € (+1,02 %)     BIOTALYS 3.070 € (-1,13 %)     KBC 121.700 € (+1,67 %)     IBA 17.720 € (+1,26 %)     BQUE NAT. BELGIQUE 356.000 € (+0,28 %)     OPTION 5.300 € (-1,85 %)     WDP 22.420 € (+2,00 %)     COLRUYT 36.600 € (+2,12 %)     LOTUS BAKERIES 11 620.000 € (+0,87 %)     UCB 264.600 € (+2,60 %)     ONWARD MEDICAL 2.600 € (+1,96 %)     BPOST 1.588 € (+1,40 %)     ENERGYVISION 14.800 € (0,00 %)     NEXTENSA 46.240 € (-0,44 %)     BREDERODE 104.200 € (-0,19 %)     BARCO 8.355 € (-0,77 %)     ECONOCOM GROUP 1.500 € (+1,35 %)     AGFA-GEVAERT 0.421 € (-0,24 %)     TUBIZE-FIN 227.600 € (+1,79 %)     CAMPINE 217.000 € (-1,81 %)     SYENSQO 65.500 € (+1,79 %)     BANQUP GROUP 2.080 € (+0,97 %)     CIE BOIS SAUVAGE 309.000 € (+1,31 %)     ONTEX GROUP 2.465 € (+1,44 %)     BEKAERT 39.650 € (+0,76 %)     MELEXIS 77.750 € (-0,77 %)     GIMV 45.800 € (-0,11 %)     FLUXYS BELGIUM D 19.750 € (+1,54 %)     TINC 11.340 € (-0,35 %)     GBL 79.300 € (-0,31 %)     CENERGY 22.140 € (+1,00 %)     TESSENDERLO 20.300 € (-2,17 %)     VAN DE VELDE 30.100 € (0,00 %)     EVS 27.400 € (-1,44 %)     BANIMMO A 2.840 € (-0,70 %)     DECEUNINCK 2.245 € (+2,05 %)     ORANGE BELGIUM 21.500 € (0,00 %)     ELIA GROUP 137.700 € (+1,70 %)     MONTEA 67.900 € (+2,26 %)     RECTICEL 10.860 € (-0,18 %)     WERELDHAVE BELGIUM 52.600 € (+0,38 %)  
   ASML HOLDING 1 577.800 € (-3,89 %)     ALFEN 14.630 € (-4,75 %)     DBV TECHNOLOGIES 2.810 € (+0,36 %)     SWI CAPITAL 6.300 € (-12,01 %)     AKWEL 6.780 € (+0,30 %)     SCHNEIDER ELECTRIC 275.900 € (-0,27 %)     CAPGEMINI 91.560 € (+0,93 %)     AXA 43.830 € (+0,76 %)     SHELL PLC 33.965 € (+1,10 %)     BOLLORE 4.110 € (+0,74 %)     LAKEFRONT BIOTHER. 26.340 € (+1,31 %)     CREDIT AGRICOLE 17.725 € (+1,40 %)     Coca-ColaEuropacif 93.200 € (+0,65 %)     TRIODOS BANK 26.800 € (0,00 %)     ALSTOM 15.445 € (+2,08 %)     AIRBUS 203.900 € (+2,87 %)     SANOFI 75.250 € (+3,01 %)     BAM GROEP KON 11.970 € (-1,72 %)     BOURSE DIRECT 4.780 € (0,00 %)     SAINT GOBAIN 79.860 € (+1,78 %)     PULLUP ENTERTAIN 7.740 € (-2,15 %)     ASM INTERNATIONAL 937.200 € (-5,62 %)     PROSUS 37.330 € (-2,91 %)     COMPAGNIE ODET 1 452.000 € (-0,41 %)     PLUXEE 11.640 € (+1,66 %)     PUBLICIS GROUPE SA 84.720 € (+0,31 %)     UNILEVER 54.290 € (+1,91 %)     STMICROELECTRONICS 61.780 € (-0,95 %)     BNP PARIBAS ACT.A 102.320 € (+1,15 %)     L'OREAL 387.950 € (+2,00 %)     SOITEC 111.750 € (-4,20 %)     NSI N.V. 17.340 € (+0,58 %)     PARROT 10.460 € (+2,95 %)     ING GROEP N.V. 28.230 € (+2,13 %)     AYVENS 11.810 € (+3,32 %)     ABN AMRO BANK N.V. 37.870 € (+2,27 %)     TOTALENERGIES 66.880 € (+1,46 %)     PERNOD RICARD 63.980 € (+3,23 %)     SAFRAN 353.300 € (+0,97 %)     THALES 240.400 € (+4,80 %)     LVMH 497.950 € (+3,52 %)     EUROFINS SCIENT. 69.140 € (+0,99 %)     TKH GROUP 42.880 € (-2,28 %)     ENGIE 27.170 € (+2,34 %)     MICHELIN 34.720 € (+2,12 %)     ESSILORLUXOTTICA 175.350 € (+1,36 %)     DANONE 73.960 € (+2,44 %)     BE SEMICONDUCTOR 262.000 € (-6,96 %)     ARCELORMITTAL SA 55.340 € (+6,34 %)     X-FAB 7.215 € (-5,00 %)     KERING 252.550 € (+2,77 %)     AMG 32.240 € (-1,59 %)     FLOW TRADERS 25.800 € (-0,08 %)     VINCI 126.900 € (+2,09 %)     WOLTERS KLUWER 57.580 € (+0,66 %)     STELLANTIS NV 5.107 € (-0,74 %)     NN GROUP 76.120 € (+0,40 %)     AHOLD DEL 36.160 € (+2,84 %)     ARCADIS 32.860 € (-0,24 %)     NEXITY 7.955 € (+1,66 %)  
News Réglementées
23/06/2026 06:30

Lonza Publishes Restated Half-Year 2025 Financials Reflecting Capsules & Health Ingredients as Discontinued Operations

Lonza Group AG / Key word(s): Miscellaneous
Lonza Publishes Restated Half-Year 2025 Financials Reflecting Capsules & Health Ingredients as Discontinued Operations

23-Jun-2026 / 06:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Ad hoc announcement pursuant to Art. 53 LR

  • Lonza reports restated Half-Year 2025 financials, reflecting Capsules & Health Ingredients (CHI) as discontinued operations, aligned with Full-Year 2025 reporting
  • Restatement includes updated consolidated income statement and selected key performance measures

Basel, Switzerland, 23 June 2026 – Prior to the release of its Half-Year 2026 results on 22 July, Lonza has published restated Half-Year 2025 financial information reflecting the classification of its CHI business as discontinued operations, in line with its Full-Year 2025 reporting. 

In December 2024, Lonza announced its intention to divest the CHI business. As a result, the CHI results were reported as discontinued operations for the Full-Year 2025. On 6 March 2026, Lonza entered into a definitive agreement to divest the CHI business to Lone Star Funds, with closing expected in Q3 2026.

The restatement includes the consolidated income statement and selected key performance measures. The restatement has no impact on Lonza’s previously reported Full-Year 2025 results. 

The restated Half-Year 2025 financial information is available at the following link.

About Lonza

Lonza is the world’s leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry. Working across five continents, Lonza’s global team of approximately 20,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. This enables customers to bring life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.

Our company generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. Find out more at www.lonza.com

Lonza Contact Details

Daniel Buchta
Head of Investor Relations
Lonza Group Ltd
Tel +41 61 316 2985
daniel.buchta@lonza.com

Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
victoria.morgan@lonza.com


End of Inside Information
Language:English
Company:Lonza Group AG
Münchensteinerstrasse 38
4052 Basel
Switzerland
Phone:+4161 316 81 11
Internet:www.lonza.com
ISIN:CH0013841017
Valor:1384101
Listed:SIX Swiss Exchange
EQS News ID:2351296

 
End of AnnouncementEQS News Service

2351296  23-Jun-2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière